Compare ITP & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITP | NXTS |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | China | Israel |
| Employees | N/A | 9 |
| Industry | Paper | Agricultural Chemicals |
| Sector | Basic Materials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 3.6M |
| IPO Year | 2020 | N/A |
| Metric | ITP | NXTS |
|---|---|---|
| Price | $0.19 | $5.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 261.4K | 42.3K |
| Earning Date | 05-12-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $75,837,943.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $0.55 |
| 52 Week High | $0.39 | $6.75 |
| Indicator | ITP | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 48.43 | 58.86 |
| Support Level | $0.19 | $3.97 |
| Resistance Level | $0.20 | $6.23 |
| Average True Range (ATR) | 0.01 | 0.72 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 41.08 | 48.53 |
IT Tech Packaging Inc is a holding company engaged in the business of paper manufacturing in China. The company operates as a producer and distributor of paper products. It is involved in the production and distribution of three categories of paper products: packing paper (corrugating medium paper), offset printing paper, and tissue paper products. It also produces digital photo paper. Its business is structured into three segments: Dongfang Paper and Tengsheng Paper, which produce offset printing paper, corrugating medium paper, and tissue paper, and Baoding Shengde, which produces face masks and digital photo paper.
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.